Atherectomy Devices: At the Cutting Edge of Peripheral Vascular Disease
This article was originally published in Start Up
Executive Summary
In the past, many medical device companies have seen PVD as a smaller offshoot of the coronary market and have sought to tap the opportunity primarily as a kind of commercial and technological second thought. Thus, they've largely tried to adapt devices developed for the coronary vasculature to peripheral applications-stents are the best example-only to fail, not because the market for PVD devices isn't there, but because significant differences between the anatomy of the peripheral and coronary vasculature mean that coronary devices don't always translate well to this new area. Now, though, as suggested by the success of FoxHollow, which recently went public, one of the most product areas for PVD may be a technology that has been around for a long time in coronary therapy but has gained a shaky reputation: atherectomy. New companies with interventional plaque clearing technologies-Cardiovascular Systems, Pathway Medical, and Minnow Medical-are thus targeting PVD first, coronary arteries, second.
You may also be interested in...
What's Next for Cardiovascular Systems?
Cardiovascular Systems beat out 119 other suitors for the right to purchase publicly traded biopharma company, Replidyne, which had fallen on hard clinical times, or, more precisely, to acquire the company's place on the public markets. But now what? With CVS headed toward the public market, it will be interesting to see how the company is valued by public investors after its merger is complete. This month, we survey small cap medical device companies that are in similar situations to see how they're faring on the public markets.
What's Next for Cardiovascular Systems?
Cardiovascular Systems beat out 119 other suitors for the right to purchase publicly traded biopharma company, Replidyne, which had fallen on hard clinical times, or, more precisely, to acquire the company's place on the public markets. But now what? With CVS headed toward the public market, it will be interesting to see how the company is valued by public investors after its merger is complete. This month, we survey small cap medical device companies that are in similar situations to see how they're faring on the public markets.
The Fischell Family's Secret of Success
Meet the Fischells. Four members of one family are collectively responsible for filing more than 200 patents in the medical device field, founding more than 14 device companies, including NeuroPace, Neuralieve, Angel Medical, Svelte Medical and GlucoTec, and inventing the world's most widely-used implantable medical device in the history of the industry, the stent design sold by Johnson & Johnson as the Bx Velocity. START-UP interviews the four Fischells to learn the secrets of their success.